Phase II trial of 17-AAG in melanoma patients
Phase II trial of 17-AAG in melanoma patients
批准号:
7244116
负责人:
PAUL B CHAPMAN
金额:
$34.42万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-19 至 2009-04-30
关键词:
AddressAnimal ModelAnimalsApplications GrantsBRAF geneBiopsyCDK4 geneCancer CenterCancer PatientCell LineClientClinicalClinical TrialsCyclin D1DoseFundingFunding MechanismsGeldanamycinGenesGoalsGrowthHSP 90 inhibitionHeat-Shock Proteins 90ImmunohistochemistryIn VitroInstitutionLeadMAP Kinase GeneMalignant NeoplasmsMeasurableMemorial Sloan-Kettering Cancer CenterMetastatic MelanomaMitogen-Activated Protein KinasesMutateMutationNRAS geneNew AgentsNew JerseyPathway interactionsPatientsPatternPhasePhase I Clinical TrialsPhase II Clinical TrialsProteinsProto-Oncogene Proteins c-aktRateReportingSpecimenTestingWeekWestern BlottingXenograft Modelcancer typecell growthcohorthuman BRAF proteininhibitor/antagonistinterestmelanocytemelanomamutantraf Kinasesresearch studyresponsetumor
中文摘要
描述(申请人提供):40-67%的黑色素瘤肿瘤含有和激活BRAF突变(几乎总是V599E)。在BRAF的上游,在另外5%-36%的黑色素瘤中可以看到N-RAS的激活突变。因此,在大多数黑色素瘤中都可以看到Mark通路中的激活突变。这些观察以及许多体外和动物研究表明,Mark通路对黑色素瘤的生长至关重要。我们的总体目标是干扰黑色素瘤的Mark通路作为一种治疗策略。BRAF依赖于HSP90进行正确的折叠,有证据表明突变的BRAF更依赖于HSP90。17-AAG抑制HSP90会导致BRAF在细胞系和异种移植模型中的耗竭,并抑制细胞生长。在黑色素瘤中被17-AAG去除的其他感兴趣的HSP90客户蛋白是CDK4和AKT。在各种癌症类型中使用17-AAG进行的I期研究已经将每周450毫克/平方米的剂量定义为最有希望的II期剂量。虽然很少有黑色素瘤患者被纳入这些I期试验,但已有一些临床反应的报道。我们建议将17-AAG用于转移性黑色素瘤患者的II期试验,剂量为450 mg/m2/周,每8周×6次。两个队列各25名患者将接受治疗-一个队列患有野生型BRAF,另一个队列患有突变BRAF。试验将在癌症研究所的MSKCC(牵头机构)进行。和H.Lee Moffitt癌症中心。具体目标#1:确定每个队列中的临床反应率,并检验BRAF突变的肿瘤对17-AAG更敏感的假设。具体目标#2:验证17-AAG治疗可以通过耗尽肿瘤内存储的BRAF和/或下游蛋白(如磷酸化ERK、CDK4和细胞周期蛋白D1)来扰乱MAPK途径的假设。为了解决这一问题,我们将在治疗前和第一次17-AAG治疗后18-48小时内对前10名患者进行肿瘤活检。对肿瘤进行免疫印迹和免疫组织化学分析。第二个目的是确定对MAPK通路的影响是否与临床反应或肿瘤中突变的BRAF的存在相关。我们还打算通过表达阵列分析来分析活检组织。作为探索性分析,我们将比较治疗前和治疗后标本、临床反应肿瘤和无反应肿瘤以及突变型BRAF和野生型BRAF肿瘤中的表达模式。
英文摘要
DESCRIPTION (provided by applicant): Between 40-67% of melanoma tumors contain and activating BRAF mutations (almost always V599E). Upstream of BRAF, activating mutations in N-RAS are seen in another 5-36% of melanomas. Thus, activating mutations in the MARK pathway are seen in most melanomas. These observations along with many in vitro and animal studies indicate that the MARK pathway is critical for melanoma growth. Our overall objective is to interfere with the MARK pathway in melanoma as a treatment strategy. BRAF depends on HSP90 for proper folding and there is evidence that mutated BRAF is even more dependent on HSP90. Inhibition of HSP90 by 17-AAG results in depletion of BRAF in cell lines and in xenograft models and inhibition of cell growth. Other HSP90 client proteins of interest in melanoma depleted by 17-AAG are CDK4 and AKT. Phase I studies using 17-AAG in a variety of cancer types have defined a weekly dose of 450 mg/m2 as the most promising phase II dose. Although few melanoma patients have been included in these phase I trials, some clinical responses have been reported. We propose a phase II trial of 17-AAG in patients with metastatic melanoma at a dose of 450 mg/m2/week x 6 every 8 weeks. Two cohorts of 25 patients each - one cohort with wild-type BRAF and one cohort with mutant BRAF - will be treated. The trial will be conducted at MSKCC (lead institution), Cancer Inst. of New Jersey, and H.Lee Moffitt Cancer Center. Specific aim #1: Determine the clinical response rate in each cohort and test the hypothesis that tumors with mutant BRAF will be more sensitive to 17-AAG. Specific aim #2: Test the hypothesis that treatment with 17-AAG can disrupt the MAPK pathway by depleting intra-tumor stores of BRAF and/or downstream proteins such as phospho-ERK, CDK4 and cyclin D1. To address this, we will obtain tumor biopsies in the first 10 patients pre-treatment and 18-48 hr following the first 17-AAG treatment. Tumors will be analyzed by Western blot and immunohistochemistry. A secondary aim is to determine if effects on the MAPK pathway correlate with clinical responses or with the presence of mutated BRAF in the tumor. We also intend to analyze the biopsies by expression array profiling. As an exploratory analysis, we will compare expression patterns in pre-treatment vs. post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1158/1078-0432.ccr-08-1002
发表时间:
2008-12-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB]
通讯作者:
Chapman PB
Phase II trial of 17-AAG in melanoma patients
-
批准号:7111952
-
项目类别:
-
资助金额:$37.98万
-
财政年份:2006
-
负责人:PAUL B CHAPMAN
-
依托单位:
Anti-GD3 NKT cells as effector cells against melanoma
-
批准号:6752082
-
项目类别:
-
资助金额:$28.01万
-
财政年份:2003
-
负责人:PAUL B CHAPMAN
-
依托单位:
Anti-GD3 NKT cells as effector cells against melanoma
-
批准号:6901866
-
项目类别:
-
资助金额:$28.01万
-
财政年份:2003
-
负责人:PAUL B CHAPMAN
-
依托单位:
Anti-GD3 NKT cells as effector cells against melanoma
-
批准号:7037582
-
项目类别:
-
资助金额:$27.35万
-
财政年份:2003
-
负责人:PAUL B CHAPMAN
-
依托单位:
Anti-GD3 NKT cells as effector cells against melanoma
-
批准号:6687393
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2003
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
-
批准号:6174304
-
项目类别:
-
资助金额:$10.51万
-
财政年份:1999
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
-
批准号:2834780
-
项目类别:
-
资助金额:$10.72万
-
财政年份:1999
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
-
批准号:6633386
-
项目类别:
-
资助金额:$10.74万
-
财政年份:1999
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
-
批准号:6377132
-
项目类别:
-
资助金额:$10.58万
-
财政年份:1999
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
-
批准号:6513542
-
项目类别:
-
资助金额:$10.66万
-
财政年份:1999
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION WITH BEC2 ANTIID VACCINE AND GD3-LACTONE
-
批准号:2896453
-
项目类别:
-
资助金额:$14.16万
-
财政年份:1998
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION WITH BEC2 ANTIID VACCINE AND GD3-LACTONE
-
批准号:2657927
-
项目类别:
-
资助金额:$13.75万
-
财政年份:1998
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST GD3 USING ANTIIDIOTYPIC MAB BEC2
-
批准号:2110263
-
项目类别:
-
资助金额:$7.51万
-
财政年份:1995
-
负责人:PAUL B CHAPMAN
-
依托单位:
IMMUNIZATION AGAINST GD3 USING ANTIIDIOTYPIC MAB BEC2
-
批准号:2110262
-
项目类别:
-
资助金额:$7.39万
-
财政年份:1995
-
负责人:PAUL B CHAPMAN
-
依托单位:
MELANOMA IMMUNOTHERAPY WITH ANTI-ID MONOCLONAL AB
-
批准号:3201703
-
项目类别:
-
资助金额:$9.86万
-
财政年份:1992
-
负责人:PAUL B CHAPMAN
-
依托单位:
MELANOMA IMMUNOTHERAPY WITH ANTI-ID MONOCLONAL AB
-
批准号:3201701
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1992
-
负责人:PAUL B CHAPMAN
-
依托单位:
海外基金